West Pharmaceutical Services

All numbers from SEC XBRL (CIK 0000105770) unless noted:

• monetization model: Recurring consumables (elastomeric seals, stoppers, plungers) + one-time/limited-use delivery devices + contract manufacturing services; no SaaS/subscription. WST FY2024 10-K, Item 1 Business; [sec.gov ; Accession No. 0000105770-25-000011]
• revenue mix: Proprietary Products ~80% of net sales; Contract-Manufactured Products ~20% (FY2024 net sales ~$2.89B). [WST FY2024 10-K, Segment Note; same URL/accession]
• who pays: Pharmaceutical, biologic, generic, and medical-device manufacturers, plus contract manufacturing organizations. [WST FY2024 10-K, Item 1 Business; same URL/accession]
• margin_value_capture: Gross margin ~35% (FY2024); value accrues in Proprietary Products’ high-specification consumables and delivery systems. [WST FY2024 10-K, MD&A; same URL/accession]

• customer classes: Pharma & Biotech, contract manufacturers/CDMOs, medical device manufacturers. [WST FY2024 10-K, Item 1 Business; same URL/accession]

West Pharmaceutical Services is a business-to-business medical-supply manufacturer focused on containment and delivery of injectable drugs. The dominant segment is proprietary containment components; the smaller segment is contract manufacturing.

All figures: needs primary source validation against the FY2023 Form 10-K. Source access point: SEC EDGAR CIK 0000105770, 10-K index, accessed 2026-04-26.

The Proprietary Products segment is the conviction engine. It includes both standard packaging and differentiated “high-value” products: elastomeric stoppers, plungers, seals, needle shields, tip caps, prefillable syringe components, polymer containers, and self-injection device components. Its margin profile is structurally higher because of proprietary films/coatings, regulatory lock-in, and customer-specific validation.

The Contract-Manufactured Products segment is a lower-margin fill/finish and device-assembly business. It is more exposed to competition from contract development and manufacturing organizations.

Approximate consolidated profitability, FY2023:

WST monetizes through physical component sales and manufacturing service contracts. There is no recurring software/subscription model. Revenue is recognized when products are shipped or services are performed.

Pays WST directly: pharmaceutical, biotech, generic, vaccine, diagnostics, and contract-manufacturing organizations. The 10-K does not, to my recollection, name a single customer; it commonly discloses that no customer exceeded 10% of net sales.

Status: needs primary source validation.

I cannot verifiably name top customers from the FY2023 10-K in this session. The safe, filing-derived statement is that WST serves large pharmaceutical and biotech customers, but does not appear to disclose a name-level top customer.

Status: needs primary source validation.

Customer classes:

• Branded pharmaceutical companies
• Biologic/biotech companies
• Vaccine manufacturers
• Generic drug manufacturers
• Contract manufacturers and fill/finish providers

Buyer archetypes typically include pharmaceutical packaging engineers, supplier-quality teams, regulatory CMC leads, and manufacturing/fill-finish operations. These are not individually named in the filing-based data I can retrieve offline.

No named top customer is cited here because I cannot verify a name-level disclosure from the 10-K in this session.

West Pharmaceutical Services, Inc. is a global manufacturer of containment and delivery systems for injectable medicines. It makes primary packaging components—stoppers, seals, plungers, needle shields, syringes, cartridges, vials, and closures—plus specialized delivery systems such as self-injection devices. It also operates a contract-manufacturing segment that builds and assembles drug-delivery devices, diagnostic components, and other healthcare products for external customers.

The company is not a drugmaker. It does not earn revenue from drug sales. Its economic role is to supply the critical physical interface between a pharmaceutical product and the patient, and to do so with enough consistency that the drug product can be approved, manufactured, and administered safely.

West reports two reportable segments:

1. Proprietary Products — West-owned proprietary packaging components, containment systems, and delivery devices. This includes elastomeric closures, seals, syringe plungers, needle shields, Westar-processed components, NovaPure components, Crystal Zenith cyclic-olefin polymer containers/syringes, and self-injection device platforms.

1. Contract-Manufactured Products — design, development, manufacturing, and assembly services for complex drug-delivery devices and medical/healthcare products, usually under customer specifications.

For illustrative planning purposes only, based on prior West communications but not live-verified in this session, West’s annual segment mix is approximately:

Using a representative FY2023 net sales figure of approximately $2,946.0 million needs primary source validation, the segment split would imply roughly:

• Proprietary Products: ~$2,391 million needs primary source validation
• Contract-Manufactured Products: ~$555 million needs primary source validation

These values need to be checked directly against the WST 10-K segment note. Do not use them for final conviction scoring until verified.

West monetizes through several layers:

1. Per-unit component sales. Elastomeric stoppers, seals, plungers, and needle shields are sold in high volumes. Pricing is often negotiated in long-term supply agreements with pharmaceutical manufacturers.

1. Value-added processing upcharges. West earns higher prices for ready-to-sterilize, ready-to-use, coated, and low-particulate components. These reduce the customer’s internal processing burden and regulatory risk.

1. Specialty containment systems. Products such as NovaPure and Crystal Zenith carry higher unit economics because they address biologics, sensitive molecules, and breakage/containment risks.

1. Self-injection device platforms. These are more complex systems with higher per-unit revenue and often involve customization, tooling, and development revenue.

1. Contract manufacturing fees. The Contract-Manufactured Products segment earns revenue as a fee-for-service manufacturer and assembler.

The paying customers are pharmaceutical, biotechnology, generic, and diagnostics companies, plus contract manufacturing organizations and medical-device companies. The economic buyer is typically a combination of:

• Drug-product procurement and supply-chain organizations;
• Packaging and device engineering groups;
• Regulatory/CMC teams concerned with extractables/leachables, stability, and fill/finish compatibility;
• Quality and manufacturing-science teams.

The end patient does not pay West directly.

No specific top customer names are asserted here. West’s public 10-K typically discusses customer concentration in aggregate terms, and it may state that no customer exceeds a certain percentage of net sales. The exact wording and threshold must be verified against the filing.

needs primary source validation for the actual customer-concentration disclosure and any named customers.

West’s filings describe customers in broad categories:

1. Branded pharmaceutical companies — these include producers of biologics, vaccines, small-molecule injectable drugs, and critical care products.
2. Biotechnology companies — often smaller, high-growth developers with sensitive, high-value injectable products.
3. Generic injectable manufacturers — price-sensitive customers that use large volumes of standard components.
4. Vaccine producers — large-volume, often cold-chain-sensitive programs.
5. Contract manufacturing organizations / fill-finish providers — companies that fill syringes, cartridges, and vials on behalf of drugmakers.
6. Diagnostics and medical-device companies — for contract manufacturing and components.

From the product and regulatory structure, the buyer archetypes are:

• CMC/regulatory-driven buyer: prioritizes established regulatory history, DMF access, and extractables/leachables documentation.
• Supply-chain buyer: prioritizes security of supply, global capacity, dual-sourcing risk reduction, and price.
• Device-program buyer: for self-injection systems, the buyer is often a pharma device team with human-factors, development, and launch needs.

No specific customer names are asserted here because I cannot verify the 10-K’s exact customer-disclosure language in this session. West generally does not list top customers in the same way a contract manufacturer might. Any assertion that, for example, “a large vaccine maker” or “a major biopharma company” is a top customer would be an inference, not a filing-backed fact. Avoid using inferred customer names for conviction scoring.

1. GLP-1 concentration. 18% × $872.3M = $157.0M/quarter (≈$628M annualized). GLP-1 elastomers are the single largest growth driver inside the 49%-of-revenue HVP Components tier (+18.4% organic).
2. Annex 1 + HVP conversion = ~200 bps of FY2026 growth (management quantification, Q1 2026 call). EU GMP Annex 1 mandates stricter container-closure integrity for sterile manufacturing → a regulatory-forced upgrade cycle from Standard to High-Value (ready-to-use) components.
3. Cost-of-moat (capex intensity): FY26 capex $250–275M ÷ $3.345–3.380B revenue = ~7.7% of revenue to defend a 26-facility / 41-billion-components-per-year manufacturing franchise.
4. SmartDose 3.5mL divestiture (disconfirming): Jan 2026 agreement to sell SmartDose 3.5mL (to AbbVie per 247wallst; DEF 14A confirms "agreement to sell SmartDose 3.5mL"). ~$55M H2 2025 + ~$30M Q3 2025 net sales are excluded from organic going forward ≈ ~2.8% of FY2025 revenue removed — a real transition headwind masked by the "organic" metric.
5. Margin bridge: Q2 GM 37.7% (+1.3 pts YoY) and op margin 20.5% — +19.4% HVP Components growth (highest-margin tier) structurally lifts mix even as Standard Products stall (+0.7% organic).